Twist Bioscience (TWST) AI Stock Analysis

• Market Cap: $1.58B
• Dividend Yield: N/A
• Average Volume (3M): 1.67M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.50
• Revenue Growth: 22.72%
• EPS Growth: 62.11%
• Country: US
• Employees: 923
• Sector: Healthcare
• Sector Strength: 51
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.33
• Shares Outstanding: 60,360,924
• 10 Day Avg. Volume: 1,148,275
• 30 Day Avg. Volume: 1,667,669
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.31
• Enterprise Value/Revenue: 5.73
• Enterprise Value/Gross Profit: 11.65
• Enterprise Value/Ebitda: -16.83
• 1Y Price Target: $37.88
• Price Target Upside: 45.69% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 9

• Rating: 48 Neutral
• Price Target: $28.00 ▲(7.69% Upside)

Twist Bioscience's overall stock score reflects strong revenue growth and operational improvements, as highlighted in the earnings call. However, significant challenges in profitability, cash flow, and technical indicators weigh heavily on the score. The recent board appointment is a positive strategic move, but the stock's valuation remains unattractive due to ongoing losses.

Positive Factors

Financial Performance

NGS drove the quarter, delivering $55M and beating expectations.

Growth Strategy

Management signaled a shift in focus back to top-line growth, including new product launches intended to expand the SynBio market opportunity.

Profitability

Profitability was well ahead of expectations.

Negative Factors

Macro Environment

Macro headwinds have impacted new customer ramps and project orders for existing customers.

Market Reaction

TWST shares were down sharply (-10.3% vs. XBI +1%) in response to the F3Q meet and narrowing of guide.

Revenue Guidance

TWST narrowed their guide downward to $374M-$376M from $372M-$379M.

Twist Bioscience Business Overview & Revenue Model

Company Description

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.

How the Company Makes Money

Twist Bioscience generates revenue primarily through the sale of its synthetic DNA products and services. The company operates on a revenue model that is driven by the demand for custom DNA synthesis, which serves a diverse clientele from research institutions to commercial enterprises. Key revenue streams include the sale of oligonucleotides, gene fragments, and complete genes, as well as DNA libraries for various applications in research and development. Additionally, Twist has formed significant partnerships and collaborations with major companies and institutions in the biotech and pharmaceutical industries, which further enhances its market reach and contributes to its earnings. The company also benefits from recurring revenue through long-term contracts and agreements with its clients, solidifying its financial stability and growth potential.

Twist Bioscience Financial Statement Overview

Summary

Twist Bioscience is experiencing strong revenue growth and improving gross margins, but profitability and cash flow remain significant challenges. The balance sheet is stable with low leverage, but the company needs to address its negative cash flow and profitability to enhance financial health.

Income Statement

Twist Bioscience has shown consistent revenue growth, with a TTM revenue growth rate of 4.2%. However, profitability remains a challenge, as indicated by negative net profit and EBIT margins. The gross profit margin has improved to 49.2% TTM, suggesting some operational efficiency gains.

Balance Sheet

The company's debt-to-equity ratio is relatively low at 0.16 TTM, indicating conservative leverage. However, the return on equity is negative, reflecting ongoing losses. The equity ratio is stable, showing a solid capital structure despite profitability challenges.

Cash Flow

Twist Bioscience's cash flow situation is concerning, with negative operating and free cash flows. The free cash flow to net income ratio is positive, indicating some cash flow efficiency, but the overall cash flow position remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	362.27M	312.97M	245.11M	203.56M	132.33M	90.10M
Gross Profit	178.40M	133.35M	89.73M	84.23M	51.71M	28.69M
EBITDA	-123.48M	-176.71M	-174.15M	-191.55M	-143.91M	-132.09M
Net Income	-85.19M	-208.73M	-204.62M	-217.86M	-152.10M	-139.93M
Balance Sheet
Total Assets	643.61M	614.32M	776.40M	961.38M	702.10M	398.88M
Cash, Cash Equivalents and Short-Term Investments	250.80M	276.40M	336.41M	504.97M	477.86M	290.00M
Total Debt	78.15M	85.03M	94.07M	94.91M	62.92M	35.98M
Total Liabilities	165.41M	141.63M	152.97M	171.99M	121.28M	62.62M
Stockholders Equity	478.20M	472.69M	623.43M	789.38M	580.82M	336.26M
Cash Flow
Free Cash Flow	-68.71M	-69.17M	-170.25M	-226.24M	-139.31M	-152.12M
Operating Cash Flow	-51.13M	-64.09M	-142.47M	-124.39M	-112.24M	-142.25M
Investing Cash Flow	-13.64M	-3.07M	50.61M	-232.93M	156.16M	-114.65M
Financing Cash Flow	26.59M	6.89M	911.00K	270.53M	329.18M	303.73M

Twist Bioscience Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 26.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TWST, the sentiment is Negative. The current price of 26 is below the 20-day moving average (MA) of 27.12, below the 50-day MA of 32.32, and below the 200-day MA of 39.10, indicating a bearish trend. The MACD of -1.52 indicates Negative momentum. The RSI at 36.55 is Neutral, neither overbought nor oversold. The STOCH value of 26.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TWST.

Twist Bioscience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SHC	65 Neutral	$4.59B	190.92	5.14%	―	2.40%	-40.03%
ILMN	64 Neutral	$15.36B	12.39	68.11%	―	-3.32%	―
GRAL	59 Neutral	$1.18B	―	-17.68%	―	22.37%	86.08%
GH	57 Neutral	$8.41B	―	-4584.47%	―	28.74%	18.25%
Sector *	51 Neutral	$7.90B	-0.33	-41.69%	2.23%	23.45%	-1.99%
TWST	48 Neutral	$1.58B	―	-17.58%	―	22.72%	62.11%
EXAS	48 Neutral	$8.98B	―	-35.51%	―	12.56%	-464.28%

Twist Bioscience Corporate Events

Twist Bioscience Appoints Trynka Shineman Blake to Board

On August 5, 2025, Twist Bioscience appointed Trynka Shineman Blake to its Board of Directors, where she will also serve on the Audit Committee. Ms. Shineman Blake, with her extensive experience in corporate governance and digital transformation, is expected to contribute significantly to Twist’s strategic direction as the company aims for adjusted EBITDA breakeven and continued innovation. Her previous leadership roles at Vistaprint highlight her ability to drive growth and innovation, aligning with Twist’s customer-centric growth strategy.

The most recent analyst rating on (TWST) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on Twist Bioscience stock, see the TWST Stock Forecast page.